|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Stable metallic 1T-WS2 ultrathin nanosheets as a promising agent for near-infrared photothermal ablation cancer therapy显示文摘在这研究,我们在场有 NH 4+2 ultrathin nanosheets 的准备 > 用一个自底向上的热水的方法和在导致光的 photothermal 癌症的这材料的潜在的申请的置闰治疗。我们的结果表明有 150 nm 的一种尺寸的 nanosheets 在宽广在红外线附近的波长区域是高度吸水、展出的强壮的轻吸收和优秀 photostability。在里面 vitro 试验性的结果显示了 nanosheets 的好 biocompatibility。更尤其是,我们的在里面 vivo antitumor 实验说明了从有 808 nm 激光的 2 nanosheets 能高效地杀死的 1T-WS 的照耀发源的那导致光的 photothermal 脱离肿瘤房间;这些效果不仅在细胞的水平而且在老鼠的生活机关被获得。这结果可以在新奇 photothermal 治疗导致二维的分层的材料的新应用,另外的 photothermal 联系领域。 | Qin Liu Chunyang Sun Qun He Adnan Khalil Ting xiang Daobin Liu Yu Zhou Jun Wang Li Song | 2015 | Nano Research2015，8，12： | 6 |
| 2 | The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study显示文摘Objective:To assess the efficacy and safety of the novel histone deacetylase inhibitor,chidamide,in combination with cyclophosphamide,doxorubicin,vincristine,etoposide,and prednisone(Chi-CHOEP)for untreated peripheral T-cell lymphoma(PTCL).Methods:A prospective,multicenter,single arm,phase 1 b/2 study was conducted.A total of 128 patients with untreated PTCL(18–70 years of age)were enrolled between March 2016 and November 2019,and treated with up to 6 cycles with the Chi-CHOEP regimen.In the phase 1 b study,3 dose levels of chidamide were evaluated and the primary endpoint was determination of the maximumtolerated dose and recommended phase 2 dose(RP2 D).The primary endpoint of the phase 2 study was 2-year progression-free survival(PFS).Results:Fifteen patients were enrolled in the phase 1 b study and the RP2 D for chidamide was determined to be 20 mg,twice a week.A total of 113 patients were treated at the RP2 D in the phase 2 study,and the overall response rate was 60.2%,with a complete response rate of 40.7%.At a median follow-up of 36 months,the median PFS was 10.7 months,with 1-,2-,and 3-year PFS rates of 49.9%,38.0%,and 32.8%,respectively.The Chi-CHOEP regimen was well-tolerated,with grade 3/4 neutropenia occurring in approximately two-thirds of the patients.No unexpected adverse events(AEs)were reported and the observed AEs were manageable.Conclusions:This large cohort phase 1 b/2 study showed that Chi-CHOEP was well-tolerated with modest efficacy in previously untreated PTCL patients. | Wei Zhang Liping Su Lihong Liu Yuhuan Gao Quanshun Wang Hang Su Yuhuan Song Huilai Zhang Jing Shen Hongmei Jing Shuye Wang Xinan Cen Hui Liu Aichun Liu Zengjun Li Jianmin Luo Jianxia He Jingwen Wang O.A.O’Connor Daobin Zhou | 2021 | Cancer Biology & Medicine2021，18，3： | 4 |
| 3 | 2021 Chinese consensus on the diagnosis and management of primary immune thrombocytopenia in pregnancy显示文摘Immune thrombocytopenia(ITP)is an acquired disease characterized by isolated thrombocytopenia,which is one of the most common causes of thrombocytopenia during pregnancy.Women with ITP who have severe thrombocytopenia are at an increased risk for life-threatening obstetric complications.Therefore,we established this consensus statement on the diagnosis and management of ITP during pregnancy(detailed information is available in the Supplementary File,http://gffzz16e312a87a7141a5h99659kobvb0k6590.ffgz.tsg.suse.edu.cn/A978). | Zhang Xiaohui Chen Fangping Chen Xiequn Cheng Yunfeng Fang Meiyun Feng Jianming Fu Haixia Gao Hong Han Yue He Aili Hou Ming Hu Yu Huang Ruibin Huang Wenrong Jing Zhicheng Kong Peiyan Liang Aibin Liang Meiying Liu Daihong Liu Junling Liu Lin Liu Xiaowei Ma Liangming Mei Heng Ni Heyu Niu Ting Peng Jun Qiao Jianlin Ren Jinhai Song Yongping Tang Liang V Tong Tong Wang Shaoyuan Wang Xin Wang Zhao Wei Hui Wu Depei Wu Guangsheng Xu Caigang Xu Xue Xu Yajing Yang Linhua Yang Renchi Yang Tonghua Yin Chenghong Yu Li Zhang Guangsen Zhang Lei Zhang Liansheng Zhang Xi Zhao Weili Zhao Yongqiang Zhou Daobin Zhou Hu Zhou Zeping Zhu Tienan Wang Jianliu Huang Xiaojun | 2022 | Chinese Medical Journal2022，，8： | 2 |
| 4 | High-metallic-phase-concentration MO1-xWxS2 nanosheets with expanded interlayers as efficient electrocatalysts显示文摘 | Qun He Yangyang Wan Hongliang Jiang Chuanqiang Wu Zhongti Sun Shuangming Chen Yu Zhou Haiping Chen Daobin Liu Yasir A. Haleem Binghui Ge Xiaojun Wu Li Song | 2018 | Nano Research2018，11，3： | 1 |
| 5 | Telomerase gene mutation screening and telomere overhang detection in Chinese patients with acute myeloid leukemia显示文摘 | Siyi Yan Bing Han Yongji Wu Daobin Zhou Yongqiang Zhao | 2013 | Leukemia & Lymphoma2013，，7： | 1 |
| 6 | Removal of COD from landfill leachate by electro-Fenton method显示文摘 | Zhang Hui Zhang Daobin Zhou Jiayong | 2006 | J Hazard Mater2006，，135： | 1 |
| 7 | Clinical characteristics and long-term outcome of patients with POEMS syndrome in China显示文摘 | Li Jian Zhou Daobin Huang Zhen | | 0，，07： | 1 |
| 8 | Removal of COD from landfill leaehate by electro-Fenton method 显示文摘 | Zhang Hui Zhang Daobin Zhou Jiayong | 2006 | Journal of Hazardous Materials B2006，135，13： | 1 |
| 9 | Removal of COD from landfill leachate by electro-Fenton method 显示文摘 | Zhang Hui Zhang Daobin Zhou Jiayong | 2006 | Journal of Hazardous Materials B2006，135，： | 1 |
| 10 | Removal of COD from landfill leachate by electro-Fenton method显示文摘 | Zhang Daobin Zhou Jiayong | 2006 | Journal of Hazardous Materials B2006，135，： | 1 |
| 11 | Removal of CODer from landfill leachate by electro-Fenton method显示文摘 | Zhang Hui Zhang Daobin Zhou Jiayong | 2006 | Journal of Hazardous Materials2006，135，13： | 1 |
| 12 | Removal of COD from landfill leachate by electro-Fenton method 显示文摘 | Zhang Hui Zhang Daobin Zhou Jiayong | 2006 | Journal of Hazardous Materials2006，135，123： | 1 |
| 13 | Removal of COD from landfill leachate by electrO-Fenton method显示文摘 | Daobin Zhang Jiayong Zhou | 2006 | Journal of Hazardous Materials2006，135，13： | 1 |
| 14 | Removal of COD from landfill leachate by electro-Fenton method显示文摘 | Zhang Hui Zhang Daobin Zhou Jiayong | 2006 | Journal of Hazardous Materials B2006，135，123： | 1 |
| 15 | Removal of COD from landfill leachate by electro-Fenton method显示文摘 | Hui Zhang Daobin Zhang Jiayong Zhou | 2006 | Journal of Hazardous Materials2006，135，： | 1 |
| 16 | Removal of COD from landfill leachate by electro-Fenton method显示文摘 | Zhang Hui Zhang Daobin Zhou Jiayong | 2006 | Journal of Hazardous Materials2006，135，123： | 1 |
| 17 | An Open-Label Study of Pegylated Liposomal Doxorubicin,Vincristine, and Reduced-Dose Dexamethasone Combination Therapy in Newly Diagnosed Multiple Myeloma Patients in the Chinese Population显示文摘OBJECTIVE Though doxorubicin is highly activein the treatment of multiple myeloma, its toxicityprofile limits its therapeutic index. We performed thisstudy to evaluate the efficacy and safety of pegylatedliposomal doxorubicin (PLD, Caelyx^(?)), vincristine,and reduced-dose dexamethasone combinationtherapy in newly diagnosed multiple myeloma (MM)patients in a Chinese population.METHODS This was an open-label, single-armstudy in which newly diagnosed patients with MMreceived PLD 40 mg/m^2 intravenously on Day 1,vincristine 1.4 mg/m^2 intravenously (maximum 2 mg)on Day 1, and 40 mg of dexarnethasone (intravenouslyor orally) from Day 1 to Day 4. Treatment wasrepeated every 28 days for at least 4 cycles.RESULTS In the intent-to-treat (ITT) analysis, theoverall response rate was 68.29%, and the completeremission rate was 10.98%. The incidence of alladverse events was 46.34%. The most commonnon-hematologic toxicities were palmar-plantarerythrodysesthesia (13.4%) and stomatitis (6.1%).CONCLUSION PLD, vincristine, and a reduceddosedexamethasone combination (DVd) is aneffective and safe regimen in newly diagnosed MMpatients in a Chinese population. | Yang Shen Zhixiang Shen Bin Jiang Jian Hou Rong Zhan Lugui Qiu Daobin Zhou Jie Jin Juan Li Fanyi Meng Ping Zou Ting Liu Jianyong Li Chun Wang Depei Wu Jun Ma | 2009 | Clinical oncology and cancer resexreh2009，6，6： | 0 |
| 18 | Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population显示文摘 | Xin Du Daobin Zhou | 2016 | Frontiers of Medicine2016，10，4： | 0 |
| 19 | Complete blood and urine paraprotein tests as response assessments in multiple myeloma patients treated with bortezomib,cyclophosphamide,and dexamethasone显示文摘Background: This study assessed the effect of standardized efficacy markers on prognosis in patients with newly diagnosed multiple myeloma(MM)during the induction phase of treatment with bortezomib,cyclophosphamide,and dexamethasone(BCD).Methods :We retrospectively analyzed clinical data in 197 newly diagnosed MM patients treated with BCD as front-line regimen at Peking Union Medical College Hospital from January 1,2013 to December 31,2018.Results: There were 107 patients with International Staging System(ISS)III and 51 with paraprotein of light chain.Of these,77 completed nine cycles of the BCD regimen.As the number of treatment cycles increased,the proportions of serum and urine immunofixation electrophoresis(IFE)tests elevated from 40.39%to 62.22%and 16.75%to 37.78%,respectively.More than 90%of intact immunoglobulin chain MM patients were evaluated for blood M protein per cycle,but that of urinary M protein was less than 60%.The detection rate of urinary M protein in light chain MM was more than 70%per cycle.Patients with a very good partial response(VGPR)had longer progression-free survival(PFS)than those with uncertain VGPR(32 vs.26 months,p=0.0336).Of the 141 patients who completed at least four cycles without undergoing autologous hematopoietic stem cell transplantation,those who were regularly assessed at every other cycle showed more favorable PFS than those who visited irregularly(27 vs.22 months,p=0.059).Conclusion: Urinary M protein detection rate is significantly lower than that in serum,leading to an overestimation of efficacy,premature reduction of treatment intensity,and shortened PFS.Precise response assessments are critical to treatment decisions and clinical diagnoses. | Xialu Lan Fujing Zhang Chen Yang Wei Su Jianhua Du Shuangjiao Liu Miao Chen Bing Han Daobin Zhou Junling Zhuang | 2024 | Chronic Diseases and Translational Medicine2024，10，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员